Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Position...
Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press
Subjects
More information
Scope and Contents
Contents
Recently, avacopan has been approved for the treatment of ANCA-associated vasculitis (AAV). Avacopan is an inhibitor of the C5a-receptor, which plays an important role in chemotaxis and the amplification loop of inflammation in AAV. In the most recent, international guidelines avacopan is recommended as steroid-sparing agents for the management of...
Alternative Titles
Full title
Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_1026791
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_1026791
Other Identifiers
ISSN
1177-8881
E-ISSN
1177-8881
DOI
10.2147/DDDT.S341842
